Abstract

Provided is a preparation with which it is possible to promote normal decidualization of the endometrium. An agent for promoting or improving decidualization of the endometrium, the agent containing an effective amount of pyrroloquinoline quinone or a salt thereof, is prepared. Furthermore, an agent for promoting or improving cell fusion, the agent containing an effective amount of pyrroloquinoline quinone or a salt thereof, is prepared.

IPC Classes  ?

• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

[Problem] To provide a compound having the potential of being a candidate for a new photo-oxygenation catalyst different from conventionally proposed photo-oxygenation catalysts. [Solution] The above problem can be solved by a compound represented by chemical formula 1 or a salt thereof. The symbols in chemical formula 1 are as defined in the description.

IPC Classes  ?

• C07D 213/61 - Halogen atoms or nitro radicals
• A61K 31/4425 - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 31/14 - Antivirals for RNA viruses
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/06 - Peri-condensed systems
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 9/50 - Proteinases
• C12N 9/99 - Enzyme inactivation by chemical treatment

Abstract

Provided are: a novel compound that is useful for the treatment of diseases to be prevented, ameliorated, and/or treated by suppressing axon degeneration; and a pharmaceutical composition containing the same.　The present invention relates to: a compound represented by general formula (I) [in the formula, Ra, Rb, X1, R1, L1, L2, and R2 are as disclosed in the specification and as set forth in the claims] or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same.

IPC Classes  ?

• C07D 213/55 - AcidsEsters
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 38/05 - Dipeptides
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 213/56 - Amides
• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• C07D 213/82 - AmidesImides in position 3
• C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/12 - Genes encoding animal proteins

Abstract

The present invention relates to an optic nerve protecting agent containing an anti-low density lipoprotein receptor-related protein 1 (LRP1) antibody or an anti-LRP1 antibody fragment.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 27/02 - Ophthalmic agents

Abstract

The aim is to provide a novel compound that can luminesce with high brightness and be used as a luminescent substrate in a firefly bioluminescence system. Provided is a heterocyclic compound, or salt thereof, represented by the following general formula (1): 4 is independently hydrogen, an alkyl group having a carbon number of 1-4, an alkenyl group having a carbon number of 2-4, or an acyl group having a carbon number of 2-4; n is an integer of 0-4].

IPC Classes  ?

• C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

The present invention pertains to a polypeptide which (a) is composed of an amino acid sequence A which shares a sequence identity of at least 80 % with the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6, and which (b) has chitin-binding activity but does not exhibit chitin-degrading activity.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/56 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

[Problem] To provide a pharmaceutical composition for the prevention and/or treatment of cancer. [Solution] Provided is a pharmaceutical composition for administration to a subject having CXCR1+CD14+ monocytes, the pharmaceutical composition containing a compound that inhibits the activity of matrix metalloproteinase 9 (MMP-9).

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12Q 1/06 - Quantitative determination
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• G01N 33/15 - Medicinal preparations
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides a method for quantitatively detecting β-1,3-1,6-glucan separately from β-1,3-glucan and β-1,3-1,4-glucan. The present invention is a method for measuring β-1,3-1,6-glucan, the method including: a step for mixing β-glucan in a test sample, a molecule that specifically binds to a β-(1→3) bond, and a molecule that specifically binds to a β-(1→6) bond to form a complex containing the molecule that specifically binds to a β-(1→3) bond and the molecule that specifically binds to a β-(1→6) bond; a step for detecting the complex; and a step for measuring the amount of β-1,3-1,6-glucan in the test sample, on the basis of the results of the detection.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention pertains to an optical nerve protecting agent containing an anti-low density lipoprotein receptor-related protein 1 (LRP1) antibody or fragment of the anti-LRP1 antibody.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 27/06 - Antiglaucoma agents or miotics
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions

Abstract

[Problem] To develop a novel therapeutic agent for viral diseases such as corona virus infection. [Solution] A therapeutic agent or prophylactic agent for viral diseases that comprises a compound having an activity of inhibiting the function of Pin1 or a pharmaceutically acceptable salt thereof as an active ingredient.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61P 31/14 - Antivirals for RNA viruses
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/99 - Enzyme inactivation by chemical treatment
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention provides a peptide that has high myostatin inhibition activity and that has improved stability in vivo. A peptide represented by formula (1) in the description.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 31/69 - Boron compounds
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention addresses the problem of providing a novel compound that can be used as a luminescent substrate in a firefly bioluminescence system and that can emit light with high brightness. In order to solve the problem, this heterocyclic compound or a salt thereof is characterized by being represented by general formula (1) [in the formula, R1, R2, and R3each independently represent hydrogen or an alkyl group having 1-4 carbon atoms, R1and R2are optionally bound to each other to form a ring, R1or R2is optionally bound to Y1to form a ring, X represents S, O, NR422, Y1and Y2each independently represent N or CR4, each R4 independently represents hydrogen, an alkyl group having 1-4 carbon atoms, an alkenyl group having 2-4 carbon atoms, or an acyl group having 2-4 carbon atoms, and n represents an integer of 0-4].

IPC Classes  ?

• C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

[Problem] To provide a novel compound that has read-through activity and is useful as an agent for preventing or treating nonsense-mutation genetic disorders. [Solution] One embodiment of the present invention provides a compound represented by formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof (with the various substituents in formula (1) being as defined in the description).

IPC Classes  ?

• A61P 3/06 - Antihyperlipidemics
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 37/08 - Antiallergic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07C 243/28 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
• A61P 17/00 - Drugs for dermatological disorders
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine

Abstract

[Problem] To develop novel compounds having an activity of inhibiting the function of Pin1 so as to use these compounds as pharmaceutical candidate compounds. [Solution] A compound represented by formula (I) or a salt thereof, and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for fatty liver diseases, a therapeutic or prophylactic agent for obesity, and a therapeutic or prophylactic agent for COVID-19, each using the aforesaid compound or a salt thereof.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• C07C 271/26 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
• C07C 275/42 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
• C07D 319/20 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 209/82 - CarbazolesHydrogenated carbazoles
• C07D 215/16 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

Abstract

Provided is a method for producing a multicellular, three-dimensional blood brain barrier model, comprising: (i) a first seeding step for seeding a human conditionally immortalized astrocyte and a human conditionally immortalized pericyte on a medium; (ii) a first coculturing step for coculturing the seeded human conditionally immortalized astrocyte and human conditionally immortalized pericyte to obtain a coculture containing two types of cells; (iii) a second seeding step for seeding a human conditionally immortalized brain microvascular endothelial cell on a medium that contains the coculture containing the two types of cells; and (iv) a second coculturing step for coculturing the coculture containing the two types of cells and the human conditionally immortalized brain microvascular endothelial cell to obtain a multicellular, three-dimensional blood brain barrier model.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

[Problem] The purpose of the present invention is to provide a composition for suppressing loss of muscle tissue. [Solution] This composition is for suppressing loss of muscle tissue in a subject having monocytes with promoted expression of CD38 and contains a compound for inhibiting the activity of the IL-36 receptor.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention provides a method for quantitatively detecting β-1,3-1,6-glucan separately from β-1,3-glucan and β-1,3-1,4-glucan. The present invention is a method for measuring β-1,3-1,6-glucan, the method comprising: a step for mixing β glucan in a sample to be tested, a molecule that specifically binds to a β-(1→3) bond, and a molecule that specifically binds to a β-(1→6) bond to from a composite containing the molecule that specifically binds to a β-(1→3) bond and the molecule that specifically binds to a β-(1→6) bond; a step for detecting the composite; and a step for measuring the amount of β-1,3-1,6-glucan in the sample to be tested, on the basis of the results of the detection.

IPC Classes  ?

• C07K 17/14 - Peptides being immobilised on, or in, an inorganic carrier
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 11/14 - Enzymes or microbial cells immobilised on or in an inorganic carrier

Abstract

Provided is a composition capable of effectively exhibiting an effect on a change in hormonal balance. A composition is prepared which is for inhibiting reduction of testosterone and/or dihydrotestosterone and contains a cordyceps militaris derived from an eri silkworm and/or an extract thereof.

IPC Classes  ?

• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 5/26 - Androgens
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
• A61P 15/12 - Drugs for genital or sexual disordersContraceptives for climacteric disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/20 - HypnoticsSedatives
• A61P 25/24 - Antidepressants
• A61P 35/00 - Antineoplastic agents
• A61K 36/068 - Cordyceps
• A23L 31/00 - Edible extracts or preparations of fungiPreparation or treatment thereof
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention provides an orally administrable composition for hair growth or hair restoration, which contains a β-glucan as an active ingredient. An orally administrable composition for hair growth or hair restoration, which contains a β-glucan as an active ingredient, and which has a viscosity of 0.04 Pa·s or more.

IPC Classes  ?

• A61K 31/716 - Glucans
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A61K 9/08 - Solutions
• A61K 35/74 - Bacteria
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 37/02 - Immunomodulators

Abstract

Provided is a peptide having a short chain length, for example, having the number of amino acid residues of 20 or less and having a high myostatin inhibitory activity. The present invention is a peptide comprising an amino acid sequence represented by Formula (1) in the specification and having the number of amino acid residues of 20 or less.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention provides a means capable of selectively introducing a disulfide bond with respect to two free thiol groups located in a molecule of an organic compound such as a peptide, or the like, in a short time by a simple treatment and also by a chemically stable method. A nitrogen-containing compound represented by Chemical Formula 1 below or a salt thereof: The symbols shown in Chemical Formula 1 are the same as defined in the specification.

IPC Classes  ?

• C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
• C07D 471/04 - Ortho-condensed systems
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07K 1/08 - General processes for the preparation of peptides using protecting groups or activating agents using activating agents
• C07K 1/02 - General processes for the preparation of peptides in solution
• C07D 213/80 - AcidsEsters in position 3
• C07K 1/06 - General processes for the preparation of peptides using protecting groups or activating agents

Abstract

n2n+144]+XXAX-p2p+13q2q+12q+1)]+XXAX-, is used as an agent for regenerating an aggregated protein (in the formulae: X represents a nitrogen atom or a phosphorus atom; n represents an integer in the range of 7-11; p and q each independently represent an integer in the range of 2-14; |p-q|≥6 is satisfied; Ax- represents a counter anion selected from the group consisting of phosphate ions, hydrogen phosphate ions, dihydrogen phosphate ions, sulfate ions, hydrogen sulfate ions, and carboxylic acid ions; and x represents the valency of the counter anion). The molar ratio of the ion-binding salt to water of hydration in the hydrate is a value in the range of 1:1 to 1:20.

IPC Classes  ?

• C07K 1/02 - General processes for the preparation of peptides in solution

Abstract

[Problem] The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. [Solution] The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

IPC Classes  ?

• C07C 233/54 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07C 229/64 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
• C07C 233/81 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07C 235/56 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

[Problem] The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. [Solution] The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

IPC Classes  ?

• C07C 233/87 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07C 233/51 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
• C07C 233/63 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07C 235/40 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
• C07C 275/28 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
• C07C 275/36 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
• C07C 275/38 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms
• C07D 209/82 - CarbazolesHydrogenated carbazoles
• C07D 223/24 - Dibenz [b, f] azepinesHydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
• C07D 265/38 - [b, e]-condensed with two six-membered rings

Abstract

[Problem] The purpose of the invention is to develop a novel therapeutic drug for fatty liver diseases such as NASH and NAFLD. [Solution] The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

[Problem] To provide a fluorescent probe with which it is possible to selectively detect GSTP1 activity. [Solution] A nitrobenzene derivative represented by general formula (1) [in the formula, the symbols are defined as in the specification] or a salt thereof is used as a fluorescent probe for measuring glutathione-S-transferase P1 (GSTP1).

IPC Classes  ?

• C07D 311/82 - Xanthenes
• C07C 255/57 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
• C07C 317/14 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

[Problem] To provide an NMUR1 agonist having excellent NMUR1 selectivity, in particular, excellent NMUR1 selectivity at high concentrations. [Solution] A peptide represented by formula (1) set forth in the description, a pharmaceutically acceptable salt thereof, or a prodrug of either.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

[Problem] To provide a peptide that selectively activates neuromedin U receptor 2 and is chemically stable under physiological conditions. [Solution] A peptide represented by formula (1) described in the description.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to develop a therapeutic agent for inflammatory diseases such as inflammatory bowel disease and NASH, said therapeutic agent having few adverse effects and high efficacy. The present invention provides compounds represented by formula (I) or salts thereof, and a Pin1 inhibitor, pharmaceutical composition, an agent for the treatment or prevention of inflammatory disease, and an agent for the treatment or prevention of colon cancer that contain these compounds or salts.

IPC Classes  ?

• C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07C 69/753 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
• C07C 69/767 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring esterified with unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
• C07C 69/92 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
• C07C 229/60 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
• C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/86 - CarbazolesHydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
• C07D 265/38 - [b, e]-condensed with two six-membered rings
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided is a peptide having a short chain length, e.g. 20 amino acid residues or fewer, and exhibiting high myostatin inhibitory activity. The present invention is a peptide comprising an amino acid sequence represented by formula (1) in the description, and having 20 amino acid residues or fewer.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Abstract

Provided are a sebum level increasing agent and a hyaluronic acid production promoter, each of which is highly active and contains an active ingredient derived from a naturally occurring substance. The present invention provides a sebum level increasing agent and a hyaluronic acid production promoter each containing donkey-hide glue as an active ingredient.

IPC Classes  ?

• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61K 9/14 - Particulate form, e.g. powders
• A61P 17/00 - Drugs for dermatological disorders
• A61Q 19/00 - Preparations for care of the skin

Abstract

[Problem] To provide a technique with which it is possible to selectively introduce a disulfide bond into two free thiol groups positioned within the molecule of an organic compound such as a peptide by a simple process in a short time and by a chemically stable method. [Solution] A nitrogen-containing compound represented by chemical formula 1 or a salt thereof. The symbols in chemical formula 1 are as defined in the specification.

IPC Classes  ?

• C07D 213/80 - AcidsEsters in position 3
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07K 1/02 - General processes for the preparation of peptides in solution

Abstract

The present invention addresses the problem of providing a novel method for evaluating a CYP3A enzymatic activity in a human body (a phenotyping test method). The present invention relates to a method for evaluating a CYP3A enzymatic activity, in which the ratio of the concentration of a substrate involved in a CYP3A enzymatic reaction to the concentration of a product of the CYP3A enzymatic reaction in blood collected from a subject is determined as a measure for the CYP3A enzymatic activity.

IPC Classes  ?

• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

[Problem] To provide a heretofore completely different and novel peptide synthesis technique, and to provide a novel compound that enables the synthesis/creation of a novel artificial functional protein and the synthesis/creation of a novel functional peptide, as well as a production method for said compound. [Solution] A compound represented by formula (I) or a salt thereof.

IPC Classes  ?

• C08G 65/337 - Polymers modified by chemical after-treatment with organic compounds containing other elements
• C07K 1/04 - General processes for the preparation of peptides on carriers
• C07K 1/08 - General processes for the preparation of peptides using protecting groups or activating agents using activating agents
• C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
• C07K 5/06 - Dipeptides
• C07K 5/08 - Tripeptides
• C07K 5/10 - Tetrapeptides
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 17/02 - Peptides being immobilised on, or in, an organic carrier
• C07D 213/82 - AmidesImides in position 3

Abstract

[Problem] To provide a therapeutic drug that exhibits a strong, selective inhibitory activity against myostatin, and enables muscle hyperplasia and an increase in muscle mass. [Solution] A peptide selected from (a)-(d), below, or a pharmaceutically acceptable salt thereof: (a) peptides having an amino acid sequence represented by one of SEQ ID NO: 1-9 or by SEQ ID NO: 40; (b) peptides having a length of 30 amino acids or less and including an amino acid sequence represented by one of SEQ ID NO: 1-9 or by SEQ ID NO: 40; (c) peptides that selectively inhibit the activity of myostatin and have an amino acid sequence represented by one of SEQ ID NO: 1-9 or by SEQ ID NO: 40 in which 1-6 amino acids have been substituted, deleted or added; and (d) derivatives of a peptide from any of (a)-(c), above.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

In the culturing a microalga to allow an aliphatic compound comprising an oil or fat and/or an aliphatic hydrocarbon to be accumulated in the microalga, drying stress is applied to the microalga and then sulfur-deficiency stress is applied to the microalga. In this manner, TG contained in the aliphatic compound that has been accumulated in the microalga can be accumulated preferentially, and therefore TG can be produced with high efficiency.

IPC Classes  ?

• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats

Abstract

Disclosed is an aggrecanase production inhibitor containing at least one carotenoid selected from the group consisting of compounds represented by the general formula (1), the general formula (2) and the general formula (3) shown below, and their therapeutically acceptable salts, ethers, esters and isomers. ⏧Chemical formula 1] (1) ⏧Chemical formula 2] (2) ⏧Chemical formula 3] (3) (In the formulae, R1 represents a hydrogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, an aralkyl group, a halogen, a hydroxy group or an alkoxy group, which may be substituted by a heteroatom; R2 and R2' respectively represent a hydrogen, a hydroxy group or an alkoxy group; and an alkene hydrogen in the structural formula may be substituted by a halogen atom.)

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups